Logo image of KROS

KEROS THERAPEUTICS INC (KROS) Stock Fundamental Analysis

USA - NASDAQ:KROS - US4923271013 - Common Stock

15.5737 USD
+0.16 (+1.06%)
Last: 10/22/2025, 10:33:45 AM
Fundamental Rating

5

Overall KROS gets a fundamental rating of 5 out of 10. We evaluated KROS against 534 industry peers in the Biotechnology industry. KROS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KROS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

KROS had positive earnings in the past year.
KROS had a positive operating cash flow in the past year.
In the past 5 years KROS always reported negative net income.
KROS had a negative operating cash flow in each of the past 5 years.
KROS Yearly Net Income VS EBIT VS OCF VS FCFKROS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of 2.48%, KROS belongs to the top of the industry, outperforming 90.64% of the companies in the same industry.
With an excellent Return On Equity value of 2.66%, KROS belongs to the best of the industry, outperforming 91.76% of the companies in the same industry.
With an excellent Return On Invested Capital value of 0.03%, KROS belongs to the best of the industry, outperforming 89.70% of the companies in the same industry.
Industry RankSector Rank
ROA 2.48%
ROE 2.66%
ROIC 0.03%
ROA(3y)-35.3%
ROA(5y)-29.15%
ROE(3y)-38.86%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
KROS Yearly ROA, ROE, ROICKROS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

1.3 Margins

KROS has a better Profit Margin (8.06%) than 91.76% of its industry peers.
Looking at the Operating Margin, with a value of 0.13%, KROS belongs to the top of the industry, outperforming 89.70% of the companies in the same industry.
Industry RankSector Rank
OM 0.13%
PM (TTM) 8.06%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KROS Yearly Profit, Operating, Gross MarginsKROS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), KROS is destroying value.
The number of shares outstanding for KROS has been increased compared to 1 year ago.
The number of shares outstanding for KROS has been increased compared to 5 years ago.
There is no outstanding debt for KROS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KROS Yearly Shares OutstandingKROS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
KROS Yearly Total Debt VS Total AssetsKROS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

KROS has an Altman-Z score of 8.03. This indicates that KROS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.03, KROS is in the better half of the industry, outperforming 79.40% of the companies in the same industry.
There is no outstanding debt for KROS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.03
ROIC/WACC0
WACC9.35%
KROS Yearly LT Debt VS Equity VS FCFKROS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 21.11 indicates that KROS has no problem at all paying its short term obligations.
KROS has a Current ratio of 21.11. This is amongst the best in the industry. KROS outperforms 95.32% of its industry peers.
A Quick Ratio of 21.11 indicates that KROS has no problem at all paying its short term obligations.
KROS's Quick ratio of 21.11 is amongst the best of the industry. KROS outperforms 95.32% of its industry peers.
Industry RankSector Rank
Current Ratio 21.11
Quick Ratio 21.11
KROS Yearly Current Assets VS Current LiabilitesKROS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

KROS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 106.04%, which is quite impressive.
KROS shows a strong growth in Revenue. In the last year, the Revenue has grown by 85190.84%.
The Revenue for KROS have been decreasing by -18.71% on average. This is quite bad
EPS 1Y (TTM)106.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.2%
Revenue 1Y (TTM)85190.84%
Revenue growth 3Y-43.89%
Revenue growth 5Y-18.71%
Sales Q2Q%49002.7%

3.2 Future

Based on estimates for the next years, KROS will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.26% on average per year.
Based on estimates for the next years, KROS will show a very strong growth in Revenue. The Revenue will grow by 178.15% on average per year.
EPS Next Y118.16%
EPS Next 2Y5.16%
EPS Next 3Y3.86%
EPS Next 5Y10.26%
Revenue Next Year39294.7%
Revenue Next 2Y325.62%
Revenue Next 3Y182.51%
Revenue Next 5Y178.15%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
KROS Yearly Revenue VS EstimatesKROS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
KROS Yearly EPS VS EstimatesKROS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 50.24, KROS can be considered very expensive at the moment.
KROS's Price/Earnings ratio is rather cheap when compared to the industry. KROS is cheaper than 91.95% of the companies in the same industry.
KROS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.77.
The Forward Price/Earnings Ratio is negative for KROS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 50.24
Fwd PE N/A
KROS Price Earnings VS Forward Price EarningsKROS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, KROS is valued cheaply inside the industry as 97.57% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.92
EV/EBITDA -38.43
KROS Per share dataKROS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.43
PEG (5Y)N/A
EPS Next 2Y5.16%
EPS Next 3Y3.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KROS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KEROS THERAPEUTICS INC

NASDAQ:KROS (10/22/2025, 10:33:45 AM)

15.5737

+0.16 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners98.17%
Inst Owner Change0.45%
Ins Owners1.24%
Ins Owner Change4.74%
Market Cap632.60M
Revenue(TTM)232.84M
Net Income(TTM)18.77M
Analysts78.82
Price Target23.46 (50.64%)
Short Float %12%
Short Ratio11.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)797.34%
Min EPS beat(2)34.17%
Max EPS beat(2)1560.5%
EPS beat(4)2
Avg EPS beat(4)393.23%
Min EPS beat(4)-13.69%
Max EPS beat(4)1560.5%
EPS beat(8)6
Avg EPS beat(8)199.13%
EPS beat(12)9
Avg EPS beat(12)134.95%
EPS beat(16)10
Avg EPS beat(16)103.11%
Revenue beat(2)2
Avg Revenue beat(2)4964.74%
Min Revenue beat(2)543.8%
Max Revenue beat(2)9385.68%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.17%
EPS NQ rev (1m)6.68%
EPS NQ rev (3m)5.91%
EPS NY rev (1m)1978.36%
EPS NY rev (3m)233.17%
Revenue NQ rev (1m)-10.01%
Revenue NQ rev (3m)6.51%
Revenue NY rev (1m)10.81%
Revenue NY rev (3m)23.07%
Valuation
Industry RankSector Rank
PE 50.24
Fwd PE N/A
P/S 2.72
P/FCF 11.92
P/OCF 11.49
P/B 0.9
P/tB 0.9
EV/EBITDA -38.43
EPS(TTM)0.31
EY1.99%
EPS(NY)-4.48
Fwd EYN/A
FCF(TTM)1.31
FCFY8.39%
OCF(TTM)1.36
OCFY8.7%
SpS5.73
BVpS17.4
TBVpS17.4
PEG (NY)0.43
PEG (5Y)N/A
Graham Number11.02
Profitability
Industry RankSector Rank
ROA 2.48%
ROE 2.66%
ROCE 0.04%
ROIC 0.03%
ROICexc 0.76%
ROICexgc 0.76%
OM 0.13%
PM (TTM) 8.06%
GM N/A
FCFM 22.8%
ROA(3y)-35.3%
ROA(5y)-29.15%
ROE(3y)-38.86%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 144.12%
Cap/Sales 0.84%
Interest Coverage 250
Cash Conversion 3291.87%
Profit Quality 282.75%
Current Ratio 21.11
Quick Ratio 21.11
Altman-Z 8.03
F-Score8
WACC9.35%
ROIC/WACC0
Cap/Depr(3y)214.84%
Cap/Depr(5y)203.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.2%
EPS Next Y118.16%
EPS Next 2Y5.16%
EPS Next 3Y3.86%
EPS Next 5Y10.26%
Revenue 1Y (TTM)85190.84%
Revenue growth 3Y-43.89%
Revenue growth 5Y-18.71%
Sales Q2Q%49002.7%
Revenue Next Year39294.7%
Revenue Next 2Y325.62%
Revenue Next 3Y182.51%
Revenue Next 5Y178.15%
EBIT growth 1Y100.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year104.84%
EBIT Next 3Y16.61%
EBIT Next 5YN/A
FCF growth 1Y146.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y149.54%
OCF growth 3YN/A
OCF growth 5YN/A